Epidemiology and Medication Trends in Patients with Psoriasis: A Nationwide Population-based Cohort Study from Korea

Han, Ju Hee; Lee, Ji Hyun; Han, Kyung Do; Seo, Hyun-Min; Bang, Chul Hwan; Park, Young Min; Lee, Jun Young; Park, Yong Gyu

doi:10.2340/00015555-2877

Cited by 49 publications

(50 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The discrepancy could also be explained by over-representation of the more severe early-onset presentation in studies of highly selected populations. 7,22,24 Our results suggest increased incidence and prevalence rates of psoriasis among men, compared to women, in line with some, [30][31][32] but not all previous reports. 27,28 However, the absolute magnitude of the sex difference is small, and its clinical implications are therefore questionable.…”

Section: Interpretation Of the Findings And Comparison With Existing supporting

confidence: 88%

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

Schonmann

Ashcroft

Iskandar

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Psoriasis is a common chronic inflammatory skin disease associated with a heavy burden of morbidity, disability and cost. The occurrence of the disease in Israel has not been previously investigated. Objectives To provide standardized estimates of trends in psoriasis incidence, prevalence and mortality among patients in Israel between 2011 and 2017. Methods Using electronic health records from Clalit Health Services, the largest nationwide public health provider in Israel, we conducted a population‐based study investigating trends in the annual incidence and prevalence of psoriasis between the years 2011 and 2017. We report age‐ and sex‐adjusted rates, using the standard European population as a reference. Results We identified 71 094 incident psoriasis cases. The mean (SD) age of onset was 42.4 (21.0) years with a bimodal distribution, peaking in the early ‘30s and early ‘60s. Late‐onset psoriasis, occurring after 40 years of age, accounted for 51.1% of incident cases. The annual psoriasis incidence rate was constant throughout the study period (280/100 000 person‐years). Psoriasis prevalence rose from 2.5% in 2011 to 3.8% in 2017. Conclusions Psoriasis prevalence is increasing in Israel, although its incidence is stable. Clinicians and policymakers should plan to address the growing demands in the clinical, economic and societal burden of psoriasis.

show abstract

Section: Interpretation Of the Findings And Comparison With Existing supporting

confidence: 88%

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

Schonmann

Ashcroft

Iskandar

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), and inflammatory bowel disease (IBD) affect all age groups, including women of reproductive age. [1][2][3][4][5] Tumor necrosis factor (TNF), which is produced by T-cells and macrophages, is a key cytokine in the inflammatory processes of these conditions. [6][7][8] Accordingly, anti-TNF agents infliximab (IFX), adalimumab (ADA), etanercept (ETA), golimumab (GOL), and certolizumab-pegol (CZP) have become a therapeutic mainstay, and are increasingly used during pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Anti‐TNF treatment during pregnancy and birth outcomes: A population‐based study from Denmark, Finland, and Sweden

Bröms

Kieler

Ekbom

et al. 2020

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose To study the risk of preterm birth, caesarean section, and small for gestational age after anti‐tumor necrosis factor agent treatment (anti‐TNF) in pregnancy. Methods Population‐based study including women with inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, and their infants born 2006 to 2013 from the national health registers in Denmark, Finland, and Sweden. Women treated with anti‐TNF were compared with women with nonbiologic systemic treatment. Adalimumab, etanercept, and infliximab were compared pairwise. Continuation of treatment in early pregnancy was compared with discontinuation. Odds ratios with 95% confidence intervals were calculated in logistic regression models adjusted for country and maternal characteristics. Results Among 1 633 909 births, 1027 infants were to women treated with anti‐TNF and 9399 to women with nonbiologic systemic treatment. Compared with non‐biologic systemic treatment, women with anti‐TNF treatment had a higher risk of preterm birth, odds ratio 1.61 (1.29‐2.02) and caesarean section, 1.57 (1.35‐1.82). The odds ratio for small for gestational age was 1.36 (0.96‐1.92). In pairwise comparisons, infliximab was associated with a higher risk of severely small for gestational age for inflammatory joint and skin diseases but not for inflammatory bowel disease. Discontinuation of anti‐TNF had opposite effects on preterm birth for inflammatory bowel disease and inflammatory joint and skin diseases. Conclusions Anti‐TNF agents were associated with increased risks of preterm birth, caesarean section, and small for gestational age. However, the diverse findings across disease groups may indicate an association related to the underlying disease activity, rather than to agent‐specific effects.

show abstract

“…Psoriasis, a chronic, immune‐mediated, inflammatory skin disease, is a serious global problem, with the reported country prevalence ranging from 0–11.43% . The prevalence of psoriasis in East Asian countries is relatively low, although it has been reported to be increasing . In studies of the prevalence of psoriasis in China, Japan, South Korea, and Taiwan, estimates ranged from 0.12–2.14% .…”

Section: Introductionmentioning

confidence: 99%

“…1,2 The prevalence of psoriasis in East Asian countries is relatively low, although it has been reported to be increasing. 2,3 In studies of the prevalence of psoriasis in China, Japan, South Korea, and Taiwan, estimates ranged from 0.12-2.14%. 1,2,4 Differences in the expression of genes that play a role in the pathophysiology of psoriasis between Asian and Western populations have been reported, [5][6][7][8] and it is therefore important to evaluate the safety and efficacy of new therapeutic agents specifically in the Asian population.…”

Section: Introductionmentioning

confidence: 99%

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

Reich

Song

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Guselkumab, an interleukin‐23 blocker, was superior to placebo and adalimumab and well‐tolerated in phase 3 psoriasis studies (VOYAGE 1 and VOYAGE 2). This analysis evaluated the consistency of response in the Asian subpopulation in VOYAGE 1 and VOYAGE 2. Study designs were identical through week 24; patients were randomized to guselkumab, placebo, or adalimumab. Investigator's Global Assessment (IGA), Psoriasis Area and Severity Index (PASI), safety, and pharmacokinetic and immunogenicity data from VOYAGE 1 and VOYAGE 2 were pooled and compared by race (Asian, n = 199; non‐Asian, n = 1630). At week 16, treatment differences between guselkumab and placebo were 78.2 (95% confidence interval [CI], 66.9–89.6) and 76.4 (95% CI, 72.7–80.2) percentage points for IGA 0/1 (score of 0 or 1) and 70.1 (95% CI, 60.0–80.1) and 68.5 (95% CI, 64.9–72.2) percentage points for PASI 90 (≥90% improvement) in the Asian and non‐Asian populations, respectively. Treatment differences between guselkumab and adalimumab were 31.1 (95% CI, 17.7–44.6) and 16.1 (95% CI, 11.2–21.0) percentage points for IGA 0/1 and 24.9 (95% CI, 9.4–40.5) and 23.2 (95% CI, 17.7–28.6) percentage points for PASI 90 in the Asian and non‐Asian populations, respectively. Similar results were observed at week 24. Safety was generally similar between populations and among treatment groups. Median serum guselkumab concentrations over time were comparable between the populations. Comparable responses between the Asian and non‐Asian populations in this analysis suggest that the overall efficacy, safety, and the resulting benefit/risk analyses from VOYAGE 1 and VOYAGE 2 are applicable to Asian populations.

show abstract

Epidemiology and Medication Trends in Patients with Psoriasis: A Nationwide Population-based Cohort Study from Korea

Cited by 49 publications

References 0 publications

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

Incidence and prevalence of psoriasis in Israel between 2011 and 2017

Anti‐TNF treatment during pregnancy and birth outcomes: A population‐based study from Denmark, Finland, and Sweden

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

Contact Info

Product

Resources

About